Search Results

You are looking at 111 - 120 of 202 items for

  • Abstract: Arteries x
  • Abstract: Atherosclerosis x
  • Abstract: Carotid x
  • Abstract: Circulation x
  • Abstract: Ghrelin x
  • Abstract: Stroke x
  • Abstract: Veins x
  • Abstract: Heart x
  • Abstract: Cardio* x
Clear All Modify Search
Aldo Bonaventura Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Aldo Bonaventura in
Google Scholar
PubMed
Close
,
Fabrizio Montecucco Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Fabrizio Montecucco in
Google Scholar
PubMed
Close
, and
Franco Dallegri Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Franco Dallegri in
Google Scholar
PubMed
Close

The prevalence of type 2 diabetes mellitus (T2DM) is increasing all over the world. Targeting good glycemic control is fundamental to avoid the complications of diabetes linked to hyperglycemia. This narrative review is based on material searched for and obtained via PubMed up to April 2015. The search terms we used were: ‘hypoglycemia, diabetes, complications’ in combination with ‘iatrogenic, treatment, symptoms.’ Serious complications might occur from an inappropriate treatment of hyperglycemia. The most frequent complication is iatrogenic hypoglycemia that is often associated with autonomic and neuroglycopenic symptoms. Furthermore, hypoglycemia causes acute cardiovascular effects, which may explain some of the typical symptoms: ischemia, QT prolongation, and arrhythmia. With regards to the latter, the night represents a dangerous period because of the major increase in arrhythmias and the prolonged period of hypoglycemia; indeed, sleep has been shown to blunt the sympatho-adrenal response to hypoglycemia. Two main strategies have been implemented to reduce these effects: monitoring blood glucose values and individualized HbA1c goals. Several drugs for the treatment of T2DM are currently available and different combinations have been recommended to achieve individualized glycemic targets, considering age, comorbidities, disease duration, and life expectancy. In conclusion, according to international guidelines, hypoglycemia-avoiding therapy must reach an individualized glycemic goal, which is the lowest HbA1c not causing severe hypoglycemia and preserving awareness of hypoglycemia.

Open access
M Ahmid Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

Search for other papers by M Ahmid in
Google Scholar
PubMed
Close
,
C G Perry Department of Endocrinology, Queen Elizabeth University Hospitals, Glasgow, UK

Search for other papers by C G Perry in
Google Scholar
PubMed
Close
,
S F Ahmed Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

Search for other papers by S F Ahmed in
Google Scholar
PubMed
Close
, and
M G Shaikh Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

Search for other papers by M G Shaikh in
Google Scholar
PubMed
Close

Until quite recently, the management of children with growth hormone deficiency (GHD) had focussed on the use of recombinant human GH (rhGH) therapy to normalise final adult height. However, research over the past two decades that has demonstrated deficits in bone health and cardiac function, as well as impaired quality of life in adults with childhood-onset GHD (CO-GHD), has questioned this practice. Some of these studies suggested that there may be short-term benefits of rhGH in certain group of adolescents with GHD during transition, although the impact of GHD and replacement during the transition period has not been adequately investigated and its long-term benefits remain unclear. GH therapy remains expensive and well-designed long-term studies are needed to determine the cost effectiveness and clinical benefit of ongoing rhGH during transition and further into adulthood. In the absence of compelling data to justify widespread continuation of rhGH into adult life, there are several questions related to its use that remain unanswered. This paper reviews the effects of growth hormone deficiency on bone health, cardiovascular function, metabolic profile and quality of life during transition and young adulthood.

Open access
Huguette S Brink Department of Endocrinology, Maasstad Hospital, Rotterdam, The Netherlands

Search for other papers by Huguette S Brink in
Google Scholar
PubMed
Close
,
Aart Jan van der Lely Department of Endocrinology, Erasmus University MC, Rotterdam, The Netherlands

Search for other papers by Aart Jan van der Lely in
Google Scholar
PubMed
Close
, and
Joke van der Linden Department of Endocrinology, Maasstad Hospital, Rotterdam, The Netherlands

Search for other papers by Joke van der Linden in
Google Scholar
PubMed
Close

Gestational diabetes (GD) is a frequent complication during pregnancy and is associated with maternal and neonatal complications. It is suggested that a disturbing environment for the foetus, such as impaired glucose metabolism during intrauterine life, may result in enduring epigenetic changes leading to increased disease risk in adult life. Hence, early prediction of GD is vital. Current risk prediction models are based on maternal and clinical parameters, lacking a strong predictive value. Adipokines are mainly produced by adipocytes and suggested to be a link between obesity and its cardiovascular complications. Various adipokines, including adiponectin, leptin and TNF&, have shown to be dysregulated in GD. This review aims to outline biomarkers potentially associated with the pathophysiology of GD and discuss the role of integrating predictive biomarkers in current clinical risk prediction models, in order to enhance the identification of those at risk.

Open access
Antonia Ertelt Equine Clinic, Free University of Berlin, Berlin, Germany

Search for other papers by Antonia Ertelt in
Google Scholar
PubMed
Close
,
Ann-Kristin Barton Equine Clinic, Free University of Berlin, Berlin, Germany

Search for other papers by Ann-Kristin Barton in
Google Scholar
PubMed
Close
,
Robert R Schmitz Equine Clinic, Free University of Berlin, Berlin, Germany

Search for other papers by Robert R Schmitz in
Google Scholar
PubMed
Close
, and
Heidrun Gehlen Equine Clinic, Free University of Berlin, Berlin, Germany

Search for other papers by Heidrun Gehlen in
Google Scholar
PubMed
Close

This review summarizes similarities and differences between the metabolic syndromes in humans and equines, concerning the anatomy, symptoms, and pathophysiological mechanisms. In particular, it discusses the structure and distribution of adipose tissue and its specific metabolic pathways. Furthermore, this article provides insights and focuses on issues concerning laminitis in horses and cardiovascular diseases in humans, as well as their overlap.

Open access
Pinaki Dutta
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Close
,
Bhuvanesh Mahendran Department of Endocrinology, Internal Medicine, Cardiology, Hematology, Histopathology, Gastroenterology, Neurosurgery, Pharmacology, Radiodiagnosis, 4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, India

Search for other papers by Bhuvanesh Mahendran in
Google Scholar
PubMed
Close
,
K Shrinivas Reddy Department of Endocrinology, Internal Medicine, Cardiology, Hematology, Histopathology, Gastroenterology, Neurosurgery, Pharmacology, Radiodiagnosis, 4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, India

Search for other papers by K Shrinivas Reddy in
Google Scholar
PubMed
Close
,
Jasmina Ahluwalia Department of Endocrinology, Internal Medicine, Cardiology, Hematology, Histopathology, Gastroenterology, Neurosurgery, Pharmacology, Radiodiagnosis, 4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, India

Search for other papers by Jasmina Ahluwalia in
Google Scholar
PubMed
Close
,
Kim Vaiphei Department of Endocrinology, Internal Medicine, Cardiology, Hematology, Histopathology, Gastroenterology, Neurosurgery, Pharmacology, Radiodiagnosis, 4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, India

Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Close
,
Rakesh K Kochhar Department of Endocrinology, Internal Medicine, Cardiology, Hematology, Histopathology, Gastroenterology, Neurosurgery, Pharmacology, Radiodiagnosis, 4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, India

Search for other papers by Rakesh K Kochhar in
Google Scholar
PubMed
Close
,
Prakamya Gupta Department of Endocrinology, Internal Medicine, Cardiology, Hematology, Histopathology, Gastroenterology, Neurosurgery, Pharmacology, Radiodiagnosis, 4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, India

Search for other papers by Prakamya Gupta in
Google Scholar
PubMed
Close
,
Anand Srinivasan Department of Endocrinology, Internal Medicine, Cardiology, Hematology, Histopathology, Gastroenterology, Neurosurgery, Pharmacology, Radiodiagnosis, 4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, India

Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Close
,
Mahesh Prakash Department of Endocrinology, Internal Medicine, Cardiology, Hematology, Histopathology, Gastroenterology, Neurosurgery, Pharmacology, Radiodiagnosis, 4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, India

Search for other papers by Mahesh Prakash in
Google Scholar
PubMed
Close
,
Kanchan Kumar Mukherjee Department of Endocrinology, Internal Medicine, Cardiology, Hematology, Histopathology, Gastroenterology, Neurosurgery, Pharmacology, Radiodiagnosis, 4th Floor, F Block, Post Graduate Institute of Medical Education and Research, Nehru Hospital, Chandigarh 160012, India

Search for other papers by Kanchan Kumar Mukherjee in
Google Scholar
PubMed
Close
,
Viral N Shah
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Close
,
Girish Parthan
Search for other papers by Girish Parthan in
Google Scholar
PubMed
Close
, and
Anil Bhansali
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Close

The effectiveness and short-term safety of recombinant human GH (r-hGH) in acromegaly patients with GH deficiency (GHD) after treatment are not well established. The study includes ten subjects with acromegaly who had GHD treated with r-hGH for 6 months. Control groups consisted of ten age-, gender-, and BMI-matched healthy subjects and ten active acromegaly patients who were treatment naïve. Body composition, quality of life (QoL), muscle strength, lipid profile, and cardiovascular risk factors were assessed in all subjects at baseline, and the same parameters were reassessed after 6 months of therapy with r-hGH in acromegaly with GHD. Repeat magnetic resonance imaging of the sella was performed in treated subjects. Optical colonoscopy was done and biopsies were taken from multiple sites for proliferation indices (Ki67). The median duration of GHD was 17.8 months and dose of r-hGH administered was 5.7±1.5 μg/kg per day. There was improvement in bone mineral content (P=0.01), bone mineral density (P=0.04), muscle strength (P<0.001), total cholesterol (P=0.003), high-density cholesterol (P<0.001), and QoL – score (P=0.005), and reduction in low-density cholesterol (P=0.003) and triglyceride (P=0.004) after treatment. There was no change in lean body mass, total body fat, hsCRP, lipoprotein (a), and fibrinogen levels. There was a modest increase in plasminogen activator inhibitor 1 (P=0.002), but it was lower compared with healthy controls and treatment naïve acromegalics (P=0.007). Six month-r-hGH therapy improves body composition, atherogenic lipid profile, QoL, and muscle strength in GHD patients who had acromegaly. Long-term prospective studies are needed to evaluate the effect of r-hGH therapy in these patients.

Open access
Gunjan Garg Departments of Endocrinology, Obstetrics and Gynecology, Biostatics

Search for other papers by Gunjan Garg in
Google Scholar
PubMed
Close
,
Garima Kachhawa Departments of Endocrinology, Obstetrics and Gynecology, Biostatics

Search for other papers by Garima Kachhawa in
Google Scholar
PubMed
Close
,
Rekha Ramot Departments of Endocrinology, Obstetrics and Gynecology, Biostatics

Search for other papers by Rekha Ramot in
Google Scholar
PubMed
Close
,
Rajesh Khadgawat Departments of Endocrinology, Obstetrics and Gynecology, Biostatics

Search for other papers by Rajesh Khadgawat in
Google Scholar
PubMed
Close
,
Nikhil Tandon Departments of Endocrinology, Obstetrics and Gynecology, Biostatics

Search for other papers by Nikhil Tandon in
Google Scholar
PubMed
Close
,
V Sreenivas Departments of Endocrinology, Obstetrics and Gynecology, Biostatics

Search for other papers by V Sreenivas in
Google Scholar
PubMed
Close
,
Alka Kriplani Departments of Endocrinology, Obstetrics and Gynecology, Biostatics

Search for other papers by Alka Kriplani in
Google Scholar
PubMed
Close
, and
N Gupta Departments of Endocrinology, Obstetrics and Gynecology, Biostatics

Search for other papers by N Gupta in
Google Scholar
PubMed
Close

To assess the effect of vitamin D supplementation on parameters of insulin sensitivity/resistance (IS/IR) and insulin secretion in subjects with polycystic ovarian syndrome (PCOS). A prospective double-blind randomized control trial was conducted to assess the effect of vitamin D on insulin kinetics in women with PCOS. The trial was conducted in a tertiary care research hospital. A total of 36 subjects with PCOS, aged 18–35 years, were included in this study. Vitamin D3 4000 IU/day versus placebo was given once a month for 6 months and both groups received metformin. IS (by whole-body IS index or Matsuda index), IR (by homeostasis model assessment IR (HOMA-IR)), and insulin secretion (by insulinogenic index; II30) were the main outcome measures. Secondary outcome included blood pressure (BP), lipid profile, disposition index (DI), and vascular stiffness. Out of 36 subjects who consented, 32 completed the study. Subjects were randomized into two groups: group A (n=15; metformin and vitamin D 4000 IU/day) or group B (n=17; metformin and placebo). Oral glucose tolerance tests with 75 g glucose were carried out at baseline and 6 months after supplementation. Hypovitaminosis D was observed in 93.8% of all subjects with mean serum 25 hydroxy vitamin D level of 7.30±4.45 ng/ml. After 6 months of vitamin D supplementation, there was no significant difference in any of the parameters of IS/IR (area under curve (AUC)–glucose, AUC–insulin, insulin:glucose ratio, HOMA-IR, Matsuda index, insulinogenic index, and DI), II30, and cardiovascular risk factors between the two groups. Supplementation of vitamin D, at a dose of 4000 IU/day for 6 months, did not have any significant effect on parameters of IS/IR and insulin secretion in subjects with PCOS.

Open access
E N Dudinskaya
Search for other papers by E N Dudinskaya in
Google Scholar
PubMed
Close
,
O N Tkacheva
Search for other papers by O N Tkacheva in
Google Scholar
PubMed
Close
,
M V Shestakova National Research Center for Preventive Medicine, Endocrinology Research Centre, Building 10, Petroverigskiy Lane, Moscow 101990, Russian Federation

Search for other papers by M V Shestakova in
Google Scholar
PubMed
Close
,
N V Brailova
Search for other papers by N V Brailova in
Google Scholar
PubMed
Close
,
I D Strazhesko
Search for other papers by I D Strazhesko in
Google Scholar
PubMed
Close
,
D U Akasheva
Search for other papers by D U Akasheva in
Google Scholar
PubMed
Close
,
O Y Isaykina
Search for other papers by O Y Isaykina in
Google Scholar
PubMed
Close
,
N V Sharashkina
Search for other papers by N V Sharashkina in
Google Scholar
PubMed
Close
,
D A Kashtanova
Search for other papers by D A Kashtanova in
Google Scholar
PubMed
Close
, and
S A Boytsov
Search for other papers by S A Boytsov in
Google Scholar
PubMed
Close

It is known that glucose disturbances contribute to micro- and macrovascular complications and vascular aging. Telomere length is considered to be a cellular aging biomarker. It is important to determine the telomere length role in vascular structural and functional changes in patients with diabetes mellitus. We conducted a cross-sectional observational study in a high-risk population from Moscow, Russia. The study included 50 patients with diabetes and without clinical cardiovascular disease and 49 control group participants. Glucose metabolism assessment tests, measuring intima–media complex thickness and determining the presence of atherosclerotic plaques, pulse wave velocity measurement, and telomere length measurement were administered to all participants. Vascular changes were more dramatic in patients with diabetes than in the control group, and the telomeres were shorter in patients with diabetes. Significant differences were found in the vascular wall condition among diabetes patients, and there were no substantial differences in the arterial structure between patients with ‘long’ telomeres; however, there were statistically significant differences in the vascular wall condition between patients with ‘short’ telomeres. Vascular ageing signs were more prominent in patients with diabetes. However, despite diabetes, vascular changes in patients with long telomeres were very modest and were similar to the vascular walls in healthy individuals. Thus, long lymphocyte telomeres may have a protective effect on the vascular wall and may prevent vascular wall deterioration caused by glucose metabolism disorders.

Open access
Line K Johnson Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway

Search for other papers by Line K Johnson in
Google Scholar
PubMed
Close
,
Kirsten B Holven Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway
Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway

Search for other papers by Kirsten B Holven in
Google Scholar
PubMed
Close
,
Njord Nordstrand Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway

Search for other papers by Njord Nordstrand in
Google Scholar
PubMed
Close
,
Jan R Mellembakken Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway

Search for other papers by Jan R Mellembakken in
Google Scholar
PubMed
Close
,
Tom Tanbo Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway
Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway

Search for other papers by Tom Tanbo in
Google Scholar
PubMed
Close
, and
Jøran Hjelmesæth Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway
Morbid Obesity Centre, Department of Nutrition, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Gynecology, Institute of Clinical Medicine, Department of Endocrinology, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway

Search for other papers by Jøran Hjelmesæth in
Google Scholar
PubMed
Close

We aimed to examine whether a whole-grain crispbread (CB) low-fructose, low-calorie diet (LCD) might be superior to a traditional LCD based on fructose-rich liquid meal replacements (LMRs) with respect to improvement of various cardiometabolic risk factors and reproductive hormones. Parallel-group randomised controlled clinical trial. Morbidly obese women with polycystic ovarian syndrome (PCOS) were randomised to either an 8-week CB-LCD or LMR-LCD (900–1100 kcal/day, fructose 17 g/day or 85 g/day). A total of 51 women completed the study. Body weight, fat mass and waist circumference reduced by mean (s.d.) 10.0 (4.8) kg, 7.4 (4.2) kg and 8.5 (4.4) cm, with no significant differences between groups. Total-cholesterol, HDL-cholesterol and Apo-A1 were significantly reduced within both groups (all P values <0.01), with no significant between-group differences. The triacylglycerol and LDL-cholesterol levels were reduced within the LMR group only, with no significant between-group differences. Blood pressure and most measures of glucose metabolism improved significantly in both diet groups, with no significant between-group difference. Uric acid levels rose by 17.7 (46.4) and 30.6 (71.5) μmol/l in the CB and LMR group, respectively, with no significant difference between groups. Gastrointestinal discomfort was significantly and equally reduced in both intervention groups. Free testosterone index was reduced in both groups, with no significant difference between groups. Morbidly obese women with PCOS who underwent either an 8-week low or high-fructose LCD-diet had similar changes in various cardiometabolic risk factors and reproductive hormones. Registration at ClinicalTrials.gov: NCT00779571.

Open access
Maria Lola Evia-Viscarra Pediatric Endocrinology Department, Research Department, Hospital Regional de Alta Especialidad del Bajío, Boulevard Milenio 130, San Carlos la Roncha, C.P. 37660 León, Guanajuato, Mexico

Search for other papers by Maria Lola Evia-Viscarra in
Google Scholar
PubMed
Close
,
Edel Rafael Rodea-Montero Pediatric Endocrinology Department, Research Department, Hospital Regional de Alta Especialidad del Bajío, Boulevard Milenio 130, San Carlos la Roncha, C.P. 37660 León, Guanajuato, Mexico

Search for other papers by Edel Rafael Rodea-Montero in
Google Scholar
PubMed
Close
,
Evelia Apolinar-Jiménez Pediatric Endocrinology Department, Research Department, Hospital Regional de Alta Especialidad del Bajío, Boulevard Milenio 130, San Carlos la Roncha, C.P. 37660 León, Guanajuato, Mexico

Search for other papers by Evelia Apolinar-Jiménez in
Google Scholar
PubMed
Close
, and
Silvia Quintana-Vargas Pediatric Endocrinology Department, Research Department, Hospital Regional de Alta Especialidad del Bajío, Boulevard Milenio 130, San Carlos la Roncha, C.P. 37660 León, Guanajuato, Mexico

Search for other papers by Silvia Quintana-Vargas in
Google Scholar
PubMed
Close

The aim of this study was to estimate the prevalence of metabolic syndrome (MS) and its components in obese Mexican adolescents and to compare the clinical, anthropometric, and biochemical characteristics between patients with and without MS by sex. We conducted a cross-sectional study with a sample of 110 obese adolescents (boys and girls) from 8 to 16 years old (BMI ≥95th percentile), who were recruited in the pediatric obesity clinic of a third-level care hospital. A frequency analysis was used to estimate the prevalence of MS and its components, and the assessments were compared between the sexes and between the groups with and without MS using the Kruskal–Wallis test. The prevalence of MS was 62%. In order of prevalence, the following components of MS were observed in the sample: abdominal obesity (88%), high triglycerides (TG) (85%), low HDL-C (60%), hypertension (35%), and hyperglycemia (5%). In the groups with MS, hypertension (P<0.001), waist circumference (P=0.003), and TG (P=0.012) were significantly higher, and HDL-C (P<0.001) was significantly lower. In conclusion the prevalence of MS and its components is high among obese Mexican-Hispanic children. These findings show the importance of preventing and treating obesity in the early stages of life in order to decrease the incidence rates of cardiovascular disease and type 2 diabetes mellitus.

Open access
Maria Angela D'amico Section of Human Morphology, Department of Medicine and Aging Sciences, G. d'Annunzio University of Chieti–Pescara, Via Dei Vestini 31, 66013 Chieti, Italy

Search for other papers by Maria Angela D'amico in
Google Scholar
PubMed
Close
,
Barbara Ghinassi Section of Human Morphology, Department of Medicine and Aging Sciences, G. d'Annunzio University of Chieti–Pescara, Via Dei Vestini 31, 66013 Chieti, Italy

Search for other papers by Barbara Ghinassi in
Google Scholar
PubMed
Close
,
Pascal Izzicupo Section of Human Morphology, Department of Medicine and Aging Sciences, G. d'Annunzio University of Chieti–Pescara, Via Dei Vestini 31, 66013 Chieti, Italy

Search for other papers by Pascal Izzicupo in
Google Scholar
PubMed
Close
,
Lamberto Manzoli Section of Human Morphology, Department of Medicine and Aging Sciences, G. d'Annunzio University of Chieti–Pescara, Via Dei Vestini 31, 66013 Chieti, Italy

Search for other papers by Lamberto Manzoli in
Google Scholar
PubMed
Close
, and
A Di Baldassarre Section of Human Morphology, Department of Medicine and Aging Sciences, G. d'Annunzio University of Chieti–Pescara, Via Dei Vestini 31, 66013 Chieti, Italy

Search for other papers by A Di Baldassarre in
Google Scholar
PubMed
Close

Chromogranin A (CgA (CHGA)) is the major soluble protein co-stored and co-released with catecholamines and can function as a pro-hormone by giving rise to several bioactive peptides. This review summarizes the physiological functions, the pathogenic implications, and the recent use of these molecules as biomarkers in several pathological conditions. A thorough literature review of the electronic healthcare databases MEDLINE, from January 1985 to September 2013, was conducted to identify articles and studies concerned with CgA and its processing. The search strategies utilized keywords such as chromogranin A, vasostatins 1 and 2, chromofungin, chromacin, pancreastatin, catestatin, WE14, chromostatin, GE25, parastatin, and serpinin and was supplemented by the screening of references from included papers and review articles. A total of 209 English-language, peer-reviewed original articles or reviews were examined. The analysis of the retrospective literature suggested that CgA and its several bioactive fragments exert a broad spectrum of regulatory activities by influencing the endocrine, the cardiovascular, and the immune systems and by affecting the glucose or calcium homeostasis. As some peptides exert similar effects, but others elicit opposite responses, the regulation of the CgA processing is critical to maintain homeostasis, whereas an unbalanced production of peptides that exert opposing effects can have a pathogenic role in several diseases. These clinical implications entail that CgA and its derived peptides are now used as diagnostic and prognostic markers or to monitor the response to pharmacological intervention not only in endocrine tumors, but also in cardiovascular, inflammatory, and neuropsychiatric diseases.

Open access